Reply to Lipworth and Chan.
作者信息
Ambrose Christopher S, Israel Elliot, Bowen Karin, Llanos Jean-Pierre, Martin Neil, Cook Bill, Hellqvist Åsa, Korn Stephanie, Menzies-Gow Andrew, Roseti Stephanie L, Molfino Nestor A, Griffiths Janet M, Parnes Jane R
机构信息
Respiratory and Immunology, BioPharmaceuticals Medical.
Pulmonary and Critical Care Medicine, Allergy & Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE.
Abstract
摘要
相似文献
1
Reply to Lipworth and Chan.对利普沃思和陈的回复。
Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE.
2
Reply to Lipworth and Chan.对利普沃思和陈的回复。
Am J Respir Crit Care Med. 2023 Jul 15;208(2):211-212. doi: 10.1164/rccm.202305-0792LE.
3
Reply to Nannini and to Lipworth .致南尼尼和利普沃思的回复。
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1325-1326. doi: 10.1164/rccm.202006-2531LE.
4
Reply to Lipworth and Kuo: Resistance Heterogeneity and Small Airway Asthma Phenotype.对利普沃思和郭的回应：耐药异质性与小气道哮喘表型。
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1442. doi: 10.1164/rccm.201906-1274LE.
5
Reply to Lipworth : Sex Hormones and Asthma: Don't Forget Progesterone.对利普沃思的回应：性激素与哮喘：别忘了孕酮。
Am J Respir Crit Care Med. 2020 Feb 1;201(3):392-393. doi: 10.1164/rccm.201910-1941LE.
6
Reply to Lipworth : Inhaled Corticosteroids and COVID-19.对利普沃思的回复：吸入性糖皮质激素与2019冠状病毒病
Am J Respir Crit Care Med. 2020 Sep 15;202(6):900-902. doi: 10.1164/rccm.202006-2129LE.
7
Chan chan: andean alternative of the preindustrial city.陈晨：前工业化城市的安第斯替代方案。
Science. 1975 Jan 24;187(4173):219-25. doi: 10.1126/science.187.4173.219.
8
Effects of short-term Huatou Chan training on health.短期话头禅训练对健康的影响。
Explore (NY). 2022 May-Jun;18(3):306-312. doi: 10.1016/j.explore.2021.04.001. Epub 2021 Apr 16.
9
Digitoxin-like immunoreactivity in sera of mice after feeding with chinese medicine Chan Su: study of protein binding of Chan Su in normal sera, uremic sera and sera from patients with liver disease.给小鼠喂食中药蟾酥后血清中的洋地黄毒苷样免疫反应性：蟾酥在正常血清、尿毒症血清和肝病患者血清中蛋白结合情况的研究
Clin Chim Acta. 2001 Mar;305(1-2):175-9. doi: 10.1016/s0009-8981(01)00377-1.
10
Identification of angiogenesis-inhibiting peptides from Chan Su.从蟾酥中鉴定血管生成抑制肽。
Protein Expr Purif. 2019 Nov;163:105445. doi: 10.1016/j.pep.2019.105445. Epub 2019 Jun 26.
引用本文的文献
1
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.tezepelumab用于重度哮喘：一种针对多种疾病途径和患者类型的药物
J Asthma Allergy. 2024 Mar 19;17:219-236. doi: 10.2147/JAA.S342391. eCollection 2024.
本文引用的文献
1
Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?tezepelumab的疗效是否独立于重度哮喘表型？
Am J Respir Crit Care Med. 2023 Apr 19;208(1):1-3. doi: 10.1164/rccm.202304-0700ED.
2
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.特泽布尔单抗治疗重度、未控制哮喘的疗效：PATHWAY 和 NAVIGATOR 临床试验的汇总分析。
Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC.
3
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.不仅仅是一种抗嗜酸性粒细胞药物：tezepelumab治疗2型哮喘及其他疾病。
Eur Respir J. 2023 Mar 30;61(3). doi: 10.1183/13993003.02202-2022. Print 2023 Mar.
4
Consequences of severe asthma exacerbations.严重哮喘发作的后果。
Curr Opin Allergy Clin Immunol. 2023 Feb 1;23(1):44-50. doi: 10.1097/ACI.0000000000000870. Epub 2022 Dec 8.
5
Determinants of asthma control and exacerbations in moderate to severe asthma.中度至重度哮喘中哮喘控制及急性加重的决定因素
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2758-2760.e1. doi: 10.1016/j.jaip.2022.06.042. Epub 2022 Jul 5.
6
Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.胸腺基质淋巴细胞生成素：在哮喘中的作用及其作为治疗靶点的潜力。
Expert Opin Ther Targets. 2020 Aug;24(8):777-792. doi: 10.1080/14728222.2020.1783242. Epub 2020 Jun 27.
Zotero 插件